<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Endocr Connect</journal-id><journal-id journal-id-type="iso-abbrev">Endocr Connect</journal-id><journal-id journal-id-type="hwp">EC</journal-id><journal-title-group><journal-title>Endocrine Connections</journal-title></journal-title-group><issn pub-type="epub">2049-3614</issn><publisher><publisher-name>Bioscientifica Ltd</publisher-name><publisher-loc>Bristol</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29133383</article-id><article-id pub-id-type="pmc">5744630</article-id><article-id pub-id-type="doi">10.1530/EC-17-0274</article-id><article-id pub-id-type="publisher-id">EC170274</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Structured education programme for women with polycystic ovary syndrome: a randomised controlled trial</article-title><alt-title alt-title-type="lrh">H Mani et al.</alt-title><alt-title alt-title-type="short">Structured education in polycystic ovary syndrome</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Mani</surname><given-names>Hamidreza</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="corresp" rid="cor1"/></contrib><contrib contrib-type="author"><name><surname>Chudasama</surname><given-names>Yogini</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Hadjiconstantinou</surname><given-names>Michelle</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Bodicoat</surname><given-names>Danielle H</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Edwardson</surname><given-names>Charlotte</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Levy</surname><given-names>Miles J</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Gray</surname><given-names>Laura J</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Barnett</surname><given-names>Janette</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Daly</surname><given-names>Heather</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Howlett</surname><given-names>Trevor A</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Khunti</surname><given-names>Kamlesh</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Davies</surname><given-names>Melanie J</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><aff id="aff1"><label>1</label><institution>Diabetes Research Centre</institution><addr-line>Leicester Diabetes Centre, University of Leicester, Leicester General Hospital, Leicester, UK</addr-line>
</aff><aff id="aff2"><label>2</label><institution>Department of Diabetes and Endocrinology</institution><addr-line>Leicester Royal Infirmary, University Hospitals of Leicester NHS Trust, Leicester, UK</addr-line>
</aff><aff id="aff3"><label>3</label><institution>The Leicester Biomedical Research Centre</institution><addr-line>Leicester and Loughborough, UK</addr-line>
</aff><aff id="aff4"><label>4</label><institution>Department of Health Sciences</institution><addr-line>University of Leicester, Leicester, UK</addr-line>
</aff><aff id="aff5"><label>5</label><institution>Leicester Medical Group</institution><addr-line>Thurmaston Health Centre, Leicester, UK</addr-line>
</aff></contrib-group><author-notes><corresp id="cor1">Correspondence should be addressed to H Mani: <email>Hamidreza.mani@uhl-tr.nhs.uk</email></corresp></author-notes><pub-date pub-type="collection"><month>1</month><year>2018</year></pub-date><pub-date pub-type="epub"><day>13</day><month>11</month><year>2017</year></pub-date><volume>7</volume><issue>1</issue><fpage>26</fpage><lpage>35</lpage><history><date date-type="received"><day>9</day><month>11</month><year>2017</year></date><date date-type="accepted"><day>10</day><month>11</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; 2018 The authors</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>The authors</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/"><license-p><inline-graphic xlink:href="88x31.jpg"/> This work is licensed under a <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">Creative Commons Attribution-NonCommercial 4.0 International License</ext-link>.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="ec-7-26.pdf"/><abstract><sec><title>Objective</title><p>To evaluate the effectiveness of a structured education programmes in women with polycystic ovary syndrome (PCOS).</p></sec><sec><title>Methods</title><p>Single-centre, randomised controlled trial, testing a single exposure to a group-based, face-to-face, structured education programme. Inclusion criteria were women with PCOS, aged 18&#x02013;49 years inclusive and body mass index &#x02265;23&#x02009;kg/m<sup>2</sup> for black and minority ethnicities or &#x02265;25&#x02009;kg/m<sup>2</sup> for white Europeans. Primary outcome was step-count/day at 12 months. Secondary outcomes included indices of physical activity, cardiovascular risk factors, quality of life (QoL) and illness perception (IP).</p></sec><sec><title>Results</title><p>161 women were included (78 control, 83 intervention); 69% white; mean age 33.4 (<sc>s.d.</sc> 7.6) years, of whom 100 (48 intervention; 52 control) attended their 12-month visit (38% attrition). 77% of the intervention arm attended the education programme. No significant change in step-count was observed at 12 months (mean difference: +351 steps/day (95% confidence interval &#x02212;481, +1183); <italic>P</italic>&#x02009;=&#x02009;0.40). No differences were found in biochemical or anthropometric outcomes. The education programme improved participants&#x02019; IP in 2 dimensions: understanding their PCOS (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001) and sense of control (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01) and improved QoL in 3 dimensions: emotions (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05), fertility (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05), weight (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01) and general mental well-being (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01).</p></sec><sec><title>Discussion</title><p>A single exposure to structured education programme did not increase physical activity or improve biochemical markers in overweight and obese women with PCOS. However, providing a structured education in parallel to routine medical treatment can be beneficial for participants&#x02019; understanding of their condition, reducing their anxiety and improving their QoL.</p></sec></abstract><kwd-group><title>Keywords</title><kwd>polycystic ovary syndrome</kwd><kwd>structured education</kwd><kwd>physical activity</kwd><kwd>attrition rate</kwd><kwd>quality of life</kwd><kwd>illness perception</kwd></kwd-group></article-meta></front><body><sec><title>Introduction</title><p>The diagnosis of polycystic ovary syndrome (PCOS) has a major impact on a woman&#x02019;s life in relation to their reproductive health (infertility and pregnancy complication), metabolic health (increased risk of type 2 diabetes (T2D) and cardiovascular risk factors) and mental health issues (reduced QoL, depression and anxiety) (<xref rid="bib1" ref-type="bibr">1</xref>, <xref rid="bib2" ref-type="bibr">2</xref>, <xref rid="bib3" ref-type="bibr">3</xref>). Women with PCOS have described their challenges in living with PCOS (<xref rid="bib4" ref-type="bibr">4</xref>) and their dissatisfaction with lack of information around their condition (<xref rid="bib5" ref-type="bibr">5</xref>). Structured education programmes increase patients&#x02019; understanding of their condition (<xref rid="bib6" ref-type="bibr">6</xref>, <xref rid="bib7" ref-type="bibr">7</xref>) and can address the expressed needs of women with PCOS about lack of information (<xref rid="bib4" ref-type="bibr">4</xref>, <xref rid="bib5" ref-type="bibr">5</xref>). Current PCOS guidelines (<xref rid="bib2" ref-type="bibr">2</xref>) recommend lifestyle change but do not routinely recommend the use of structured education programmes. There is, however, a potential need for this (<xref rid="bib5" ref-type="bibr">5</xref>, <xref rid="bib8" ref-type="bibr">8</xref>, <xref rid="bib9" ref-type="bibr">9</xref>), and we hypothesised that an educational programme using the tested models for T2D (<ext-link ext-link-type="uri" xlink:href="http://www.desmond-project.org.uk">http://www.desmond-project.org.uk</ext-link>), might assist in lifestyle change (for example, increase physical activity) for women with PCOS by improving their understanding of their condition.</p></sec><sec><title>Subjects and methods</title><p>We conducted a single-centre, parallel randomised controlled trial (Ethical approval by East Midlands&#x02019; Research Ethics Committee 11/EM/0141, Clinical Trials.Gov registration number Nbib1462864). The intervention was a single seven-hour, group-based, face-to-face structured education programme. The study was powered to detect a mean difference of 2000 steps/day between the arms, based on a previous study in people at risk of diabetes (<xref rid="bib10" ref-type="bibr">10</xref>), where a similar intervention had increased step-counts by 2000 steps/day (standard deviation (<sc>s.d.</sc>)&#x02009;=&#x02009;4000 steps/day). Aiming for 80% power, <italic>&#x003b1;</italic>&#x02009;=&#x02009;0.05, <sc>s.d.&#x02009;</sc>=&#x02009;4000 steps/day and allowing for 20% drop out, 80 participants per arm were needed. All participants consented after full explanation of the study procedure.</p><sec><title>Inclusion/exclusion criteria</title><p>Women with a confirmed diagnosis of PCOS (<xref rid="bib2" ref-type="bibr">2</xref>), body Mass Index (BMI) (&#x02265;23&#x02009;kg/m<sup>2</sup> for black and minority; &#x02265;25&#x02009;kg/m<sup>2</sup> for white Europeans) (<xref rid="bib11" ref-type="bibr">11</xref>), aged 18&#x02013;49 years inclusive, who had stable PCOS treatment in the previous 6 months were eligible. Exclusion criteria were pregnancy, diabetes, use of corticosteroids, disabling physical or mental condition and inability to speak English.</p><p>Participants were recruited (July 2012 to July 2013) from primary care as identified by Read codes in the electronic record, PCOS clinics in the local university hospital and media advertisements.</p></sec><sec><title>Study visits and outcome measures</title><p>Visits were performed at the local research centre. At baseline, information on smoking status, ethnicity, medical and family history was obtained by self-report. Fasting blood test and oral glucose tolerance test was performed and questionnaires were filled in.</p><p>The Brief Illness Perceptions Questionnaire (BIPQ) (<xref rid="bib12" ref-type="bibr">12</xref>) was used to test PCOS perception. This nine-item instrument is based on an 11 point scale (0&#x02009;=&#x02009;no effect, 10&#x02009;=&#x02009;complete effect) to measure five cognitive illness representations (consequences, timeline, personal control, treatment control and identity), two emotional representations (concern and emotion) and illness comprehensibility (perceived knowledge).</p><p>Health-related QoL (HRQoL) was measured using disease-specific and independent generic tools. The disease-specific PCOS questionnaire (PCOSQ) (<xref rid="bib13" ref-type="bibr">13</xref>), which contains 26 items measures five areas; emotions, body hair, weight, infertility problems and menstrual problems. The independent generic HRQoL questionnaire, version 2 of the Short form F12 (SF12V2) health survey (Optum.com), includes one question for each of the total eight domains (physical functioning, social functioning, physical impairment, emotional impairment, emotions, vitality, pain and global health) (<xref rid="bib14" ref-type="bibr">14</xref>). The composite score in SF12V2 was calculated using the approved software by the company (Quality.Metrics).</p><p>Step-counts and other activity data were objectively measured by the Actigraph GT3X accelerometer (Penascola Florida, USA). At least four days of &#x02265;10&#x02009;h of accelerometer movement data were required for analysis. KineSoft (version 3.3.76) was used to process the data.</p><p>All participants left the centre wearing their accelerometer with a log-book to register their activities. They were instructed to wear the accelerometer for 10 days during the waking hours and return it in a pre-paid envelope.</p><p>Randomisation occurred after the baseline visit by an independent administrator. Randomisation was 1:1 to the intervention or control arm, stratified for age (&#x0003c;35 years or &#x02265;35 years), ethnicity (white or non-white) and current use of metformin (yes or no). The study was un-blinded due to the nature of the intervention. Participants were blind to their baseline step-counts. They were informed of randomisation after their accelerometer was returned. The intervention group was then invited to attend the next available structured education. The study team did not change the medical treatment for PCOS; both arms continued as before with their own doctors and both received a generic information sheet about PCOS and the benefits of lifestyle change.</p><p>Those with blood tests indicative of diabetes had a repeat test and if confirmed, were excluded from the study and referred to their general practitioner.</p><p>Follow-up visits had the same structure and were at 6 and 12 months after the baseline visit, irrespective of the education date for the intervention arm; both arms returned at a similar period, eliminating the seasonal effect on outdoor physical activity. The study was concluded in August 2014.</p></sec><sec><title>Intervention</title><p>A &#x02018;structured education programme to improve cardiovascular risk in women with PCOS, SUCCESS&#x02019;. The curriculum of the programme considered the available literature (<xref rid="bib2" ref-type="bibr">2</xref>, <xref rid="bib8" ref-type="bibr">8</xref>, <xref rid="bib15" ref-type="bibr">15</xref>, <xref rid="bib16" ref-type="bibr">16</xref>, <xref rid="bib17" ref-type="bibr">17</xref>, <xref rid="bib8" ref-type="bibr">18</xref>, <xref rid="bib19" ref-type="bibr">19</xref>, <xref rid="bib20" ref-type="bibr">20</xref>) and was informed by quantitative and qualitative analysis of the target population (<xref rid="bib3" ref-type="bibr">3</xref>, <xref rid="bib4" ref-type="bibr">4</xref>, <xref rid="bib21" ref-type="bibr">21</xref>). The initial drafts of the education programme were piloted in two different cohorts of women with PCOS (<italic>N</italic>&#x02009;=&#x02009;5 in each cohort) and their feedback was sought and implemented into the final draft (<xref rid="bib22" ref-type="bibr">22</xref>, <xref rid="bib23" ref-type="bibr">23</xref>).</p><p>The final programme consisted of 7&#x02009;h of interactive discussions including patient and professional story, diet and physical activity, balancing life with PCOS and self-management plan (<ext-link ext-link-type="uri" xlink:href="http://www.endocrineconnections.org/cgi/content/full/EC-17-0274/DC1">Supplementary Table 1</ext-link>, see section on <xref ref-type="supplementary-material" rid="supp1">supplementary data</xref> given at the end of this article). Each education session was delivered by two trained educators. Each participant received a resource pack including summary of the points from each section as well as the results of their glucose, lipids, BMI and average walking steps from their baseline visit so they could reflect on their results during the programme. In the section &#x02018;Balancing life with PCOS&#x02019; (<ext-link ext-link-type="uri" xlink:href="http://www.endocrineconnections.org/cgi/content/full/EC-17-0274/DC1">Supplementary Table 1</ext-link>), participants had the opportunity to share their feelings towards PCOS.</p><p>At the end of the session, participants were asked to reflect on the day.</p></sec><sec><title>Statistical analysis</title><p>Descriptive characteristics are presented as means and <sc>s.d.</sc> or medians with ranges for continuous variables depending on their distribution, and as number and percentages for categorical variables. Outcome data were assessed for normality using visual inspection of histograms. Per-protocol analysis was used, which excluded the participants who did not attend the structured education or were lost to follow-up. For the primary outcome, the mean change in steps per day at 12 months was compared between treatment arms using a linear regression model, adjusted for the stratification variables, change in accelerometer wear time and baseline step-count (Stata, version 14.0). Sensitivity analyses included complete case and intention-to-treat analysis. Subgroup analyses and secondary outcomes were analysed in a similar manner and graphically displayed with the estimated difference of steps between treatment groups with 95% confidence interval. Statistical significance was set at 5% for main effects with two-sided <italic>P</italic> values. Statistical analyses were performed using Stata (version 14.0).</p><p>The <ext-link ext-link-type="uri" xlink:href="http://www.endocrineconnections.org/cgi/content/full/EC-17-0274/DC1">Supplementary Methods</ext-link> contains further details of the methodology of sensitivity analyses as well as 6-month data.</p></sec></sec><sec><title>Results</title><p>We recruited 161 participants (78 controls, 83 intervention) (<xref ref-type="fig" rid="fig1">Fig. 1</xref>), mean age 33.4 (<sc>s.d.</sc> 7.6) years and 68.9% white ethnicity. Overall, 47.5% were working full time, 31.9% part time and 6.3% were students. Median baseline step-counts for the control and intervention arms were 6294 and 6353 steps/day, respectively (<xref ref-type="table" rid="tbl1">Table 1</xref>). Overall, 22% of the participants were current smokers.
<fig fig-type="figure" id="fig1" position="float"><label>Figure 1</label><caption><p>CONSORT flow diagram (<ext-link ext-link-type="uri" xlink:href="http://www.consort-statement.org/">http://www.consort-statement.org/</ext-link>) for the participants in SUCCESS study. BMI, Body Mass Index. <sup>&#x02021;</sup>Participants with diabetes were referred to a diabetes education programme. <sup>&#x02020;</sup>Did not meet the BMI eligibility criteria and had been incorrectly randomised.</p></caption><graphic xlink:href="ec-7-26-g001"/></fig>
<table-wrap id="tbl1" position="float"><label>Table 1</label><caption><p>Baseline characteristics of participants; values are presented as means (<sc>s.d.</sc>), medians (lower and upper quartiles) or as otherwise stated.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"><bold>Characteristics</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>Control</bold> (<italic>n</italic>&#x02009;=&#x02009;78)</th><th valign="top" align="center" rowspan="1" colspan="1"><bold>Intervention</bold> (<italic>n</italic>&#x02009;=&#x02009;83)</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Age (years)</td><td valign="top" align="center" rowspan="1" colspan="1">33.3 (8.1)</td><td valign="top" align="center" rowspan="1" colspan="1">33.4 (7.1)</td></tr><tr><td valign="top" align="left" colspan="3" rowspan="1">No (%)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;European</td><td valign="top" align="center" rowspan="1" colspan="1">53 (67.9)</td><td valign="top" align="center" rowspan="1" colspan="1">58 (69.9)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;South Asian</td><td valign="top" align="center" rowspan="1" colspan="1">17 (21.8)</td><td valign="top" align="center" rowspan="1" colspan="1">14 (16.9)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Other</td><td valign="top" align="center" rowspan="1" colspan="1">8 (10.3)</td><td valign="top" align="center" rowspan="1" colspan="1">11 (13.3)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">No (%) working full time</td><td valign="top" align="center" rowspan="1" colspan="1">48 (62.3)</td><td valign="top" align="center" rowspan="1" colspan="1">46 (55.4)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">No (%) current smokers</td><td valign="top" align="center" rowspan="1" colspan="1">15 (19.2)</td><td valign="top" align="center" rowspan="1" colspan="1">21 (25.3)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">No (%) depression</td><td valign="top" align="center" rowspan="1" colspan="1">28 (35.9)</td><td valign="top" align="center" rowspan="1" colspan="1">29 (34.9)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">No (%) metformin</td><td valign="top" align="center" rowspan="1" colspan="1">15 (19.2)</td><td valign="top" align="center" rowspan="1" colspan="1">17 (20.5)</td></tr><tr><td valign="top" align="left" colspan="3" rowspan="1">Recruitment</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Primary care</td><td valign="top" align="center" rowspan="1" colspan="1">44 (56.4)</td><td valign="top" align="center" rowspan="1" colspan="1">51 (61.5)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Secondary care</td><td valign="top" align="center" rowspan="1" colspan="1">13 (16.7)</td><td valign="top" align="center" rowspan="1" colspan="1">9 (10.8)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Self-referral</td><td valign="top" align="center" rowspan="1" colspan="1">21 (26.9)</td><td valign="top" align="center" rowspan="1" colspan="1">23 (27.7)</td></tr><tr><td valign="top" align="left" colspan="3" rowspan="1">Year of PCOS diagnosis</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x0003c;5 years</td><td valign="top" align="center" rowspan="1" colspan="1">25 (32.1)</td><td valign="top" align="center" rowspan="1" colspan="1">25 (30.1)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;5&#x02013;10 years</td><td valign="top" align="center" rowspan="1" colspan="1">13 (16.7)</td><td valign="top" align="center" rowspan="1" colspan="1">26 (31.3)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x0003e;10 years</td><td valign="top" align="center" rowspan="1" colspan="1">40 (51.3)</td><td valign="top" align="center" rowspan="1" colspan="1">32 (38.6)</td></tr><tr><td valign="top" align="left" colspan="3" rowspan="1">Biometric measurements</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Weight (kg)</td><td valign="top" align="center" rowspan="1" colspan="1">89.0 (19.6)</td><td valign="top" align="center" rowspan="1" colspan="1">90.9 (18.9)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Body Mass Index (kg/m<sup>2</sup>)</td><td valign="top" align="center" rowspan="1" colspan="1">33.2 (6.2)</td><td valign="top" align="center" rowspan="1" colspan="1">34.2 (7.2)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Systolic blood pressure (mmHg)</td><td valign="top" align="center" rowspan="1" colspan="1">121.7 (11.5)</td><td valign="top" align="center" rowspan="1" colspan="1">122.5 (13.1)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Diastolic blood pressure (mmHg)</td><td valign="top" align="center" rowspan="1" colspan="1">77.1 (10.6)</td><td valign="top" align="center" rowspan="1" colspan="1">80.4 (11.9)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Fasting glucose (mmol/L)</td><td valign="top" align="center" rowspan="1" colspan="1">4.8 (0.4)</td><td valign="top" align="center" rowspan="1" colspan="1">4.8 (0.5)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;2-h glucose (mmol/L)</td><td valign="top" align="center" rowspan="1" colspan="1">5.9 (1.4)</td><td valign="top" align="center" rowspan="1" colspan="1">5.8 (1.8)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Haemoglobin A<sub>1c</sub> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">5.7 (0.4)</td><td valign="top" align="center" rowspan="1" colspan="1">5.7 (0.4)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Haemoglobin A<sub>1c</sub> (mmol/mol)</td><td valign="top" align="center" rowspan="1" colspan="1">38.7 (4.2)</td><td valign="top" align="center" rowspan="1" colspan="1">39.2 (4.0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Total cholesterol (mmol/L)</td><td valign="top" align="center" rowspan="1" colspan="1">5.2 (0.9)</td><td valign="top" align="center" rowspan="1" colspan="1">5.0 (1.0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;HDL (mmol/L)</td><td valign="top" align="center" rowspan="1" colspan="1">1.5 (0.5)</td><td valign="top" align="center" rowspan="1" colspan="1">1.4 (0.4)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;LDL (mmol/L)</td><td valign="top" align="center" rowspan="1" colspan="1">3.2 (0.9)</td><td valign="top" align="center" rowspan="1" colspan="1">3.0 (0.8)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Triglycerides (mmol/L)</td><td valign="top" align="center" rowspan="1" colspan="1">1.3 (0.6)</td><td valign="top" align="center" rowspan="1" colspan="1">1.4 (0.7)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;HOMA-IR</td><td valign="top" align="center" rowspan="1" colspan="1">2.5 (1.6)</td><td valign="top" align="center" rowspan="1" colspan="1">2.8 (2.3)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Sex Hormone Binding Globulin (mmol/L)</td><td valign="top" align="center" rowspan="1" colspan="1">47.0 (40.3)</td><td valign="top" align="center" rowspan="1" colspan="1">56.9 (48.4)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Free Androgen Index (%)</td><td valign="top" align="center" rowspan="1" colspan="1">6.5 (6.0)</td><td valign="top" align="center" rowspan="1" colspan="1">6.8 (5.4)</td></tr><tr><td valign="top" align="left" colspan="3" rowspan="1">Physical activity</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Steps (counts/day)</td><td valign="top" align="center" rowspan="1" colspan="1">6294 (4785&#x02013;8478)</td><td valign="top" align="center" rowspan="1" colspan="1">6353 (5147&#x02013;7521)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Light PA (min/day)</td><td valign="top" align="center" rowspan="1" colspan="1">262.3 (226.8&#x02013;318.2)</td><td valign="top" align="center" rowspan="1" colspan="1">278.5 (228.2&#x02013;341.9)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;MVPA (min/day)</td><td valign="top" align="center" rowspan="1" colspan="1">28.7 (12.5&#x02013;40.7)</td><td valign="top" align="center" rowspan="1" colspan="1">26.5 (16.2&#x02013;41.1)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Sedentary (min/day)</td><td valign="top" align="center" rowspan="1" colspan="1">526.3 (479.0&#x02013;580.9)</td><td valign="top" align="center" rowspan="1" colspan="1">532.4 (473.1&#x02013;578.4)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Accelerometer wear time (min/day)</td><td valign="top" align="center" rowspan="1" colspan="1">832.4 (779.6&#x02013;886.0)</td><td valign="top" align="center" rowspan="1" colspan="1">849.7 (799.5&#x02013;877.6)</td></tr></tbody></table><table-wrap-foot><fn id="fn1"><p>Missing data: 0 age, ethnicity, depression, multimorbidity, weight, BMI, metformin; 1 working, systolic blood pressure, diastolic blood pressure; 2 total cholesterol, HDL, triglycerides, SHBG; 3 fasting glucose, HbA1c, LDL; 4 2-h glucose; 13 HOMA-IR; 23 steps, light PA, MVPA, sedentary, FAI; 80 current smoker.</p></fn></table-wrap-foot></table-wrap>
</p><p>Mean (<sc>s.d.</sc>) days from baseline to six- and 12-month visits were 217 (39) and 399 (44) for the education arm, and 207 (39) and 389 (30) days for the control arm (<italic>P</italic>&#x02009;=&#x02009;0.117 and <italic>P</italic>&#x02009;=&#x02009;0.179 for six and 12 months, respectively). For the 65 (77%) women who attended education, the mean (<sc>s.d.</sc>) time from baseline appointment to education was 90 (54) days. At 12 months, attendance was 58% (<italic>n</italic>&#x02009;=&#x02009;48) in control arm and 67% (<italic>n</italic>&#x02009;=&#x02009;52) in the education (intervention) arm amounting to 38% total dropout.</p><p>The mean difference in change in step-counts/day at 12 months was +351 (95% confidence interval: &#x02212;481, 1183) in those receiving the intervention compared to control, with similar results in sensitivity analyses (<xref ref-type="table" rid="tbl2">Table 2</xref>). Subgroup analysis for stratification factors, source of recruitment and duration of the PCOS (&#x0003c;5, 5&#x02013;10, and &#x0003e;10 years) showed no difference in outcome (<ext-link ext-link-type="uri" xlink:href="http://www.endocrineconnections.org/cgi/content/full/EC-17-0274/DC1">Supplementary Fig. 1</ext-link>). The activity log indicated that almost half of the participants had taken off their monitors during potentially relevant activities such as swimming, spinning class, running and partying: 47% in the education arm and 50% in the control. None, however, had recorded the time duration for these activities.
<table-wrap id="tbl2" position="float"><label>Table 2</label><caption><p>Change in the number of steps at 6- and 12-months and treatment difference between participants randomised to usual care (control) or the structured education (intervention).</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="2" colspan="1"/><th valign="top" align="center" colspan="2" rowspan="1"><bold>Number of participants</bold></th><th valign="top" align="center" colspan="2" rowspan="1"><bold>Mean change from baseline</bold> (95% CI)</th><th valign="top" align="center" colspan="2" rowspan="1"><bold>Model summary<sup>a</sup></bold></th></tr><tr><th valign="top" align="center" rowspan="1" colspan="1">Control</th><th valign="top" align="center" rowspan="1" colspan="1">Intervention</th><th valign="top" align="center" rowspan="1" colspan="1">Control</th><th valign="top" align="center" rowspan="1" colspan="1">Intervention</th><th valign="top" align="center" rowspan="1" colspan="1">Coefficient (95% CI)</th><th valign="top" align="center" rowspan="1" colspan="1"><italic>P</italic> value<sup>b</sup></th></tr></thead><tbody><tr><td valign="top" align="left" colspan="7" rowspan="1">Per protocol<sup>c,d</sup></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;6-months</td><td valign="top" align="center" rowspan="1" colspan="1">42</td><td valign="top" align="center" rowspan="1" colspan="1">40</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;240 (&#x02212;869, 390)</td><td valign="top" align="center" rowspan="1" colspan="1">792 (134, 1450)</td><td valign="top" align="center" rowspan="1" colspan="1">751 (&#x02212;80, 1529)</td><td valign="top" align="center" rowspan="1" colspan="1">0.076</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;12-months</td><td valign="top" align="center" rowspan="1" colspan="1">38</td><td valign="top" align="center" rowspan="1" colspan="1">34</td><td valign="top" align="center" rowspan="1" colspan="1">325 (&#x02212;365, 1016)</td><td valign="top" align="center" rowspan="1" colspan="1">651 (51, 1251)</td><td valign="top" align="center" rowspan="1" colspan="1">351 (&#x02212;481, 1183)</td><td valign="top" align="center" rowspan="1" colspan="1">0.402</td></tr><tr><td valign="top" align="left" colspan="7" rowspan="1">Complete case<sup>c</sup></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;6-months</td><td valign="top" align="center" rowspan="1" colspan="1">42</td><td valign="top" align="center" rowspan="1" colspan="1">42</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;240 (&#x02212;869, 390)</td><td valign="top" align="center" rowspan="1" colspan="1">751 (122, 1380)</td><td valign="top" align="center" rowspan="1" colspan="1">721 (&#x02212;88, 1530)</td><td valign="top" align="center" rowspan="1" colspan="1">0.080</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;12-months</td><td valign="top" align="center" rowspan="1" colspan="1">38</td><td valign="top" align="center" rowspan="1" colspan="1">34</td><td valign="top" align="center" rowspan="1" colspan="1">325 (&#x02212;364, 1015)</td><td valign="top" align="center" rowspan="1" colspan="1">651 (51, 1251)</td><td valign="top" align="center" rowspan="1" colspan="1">351 (&#x02212;480, 1183)</td><td valign="top" align="center" rowspan="1" colspan="1">0.402</td></tr><tr><td valign="top" align="left" colspan="7" rowspan="1">Intention to treat<sup>e</sup></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;6-months</td><td valign="top" align="center" rowspan="1" colspan="1">78</td><td valign="top" align="center" rowspan="1" colspan="1">83</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;205 (&#x02212;856, 446)</td><td valign="top" align="center" rowspan="1" colspan="1">707 (84, 1331)</td><td valign="top" align="center" rowspan="1" colspan="1">703 (&#x02212;71, 1476)</td><td valign="top" align="center" rowspan="1" colspan="1">0.074</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;12-months</td><td valign="top" align="center" rowspan="1" colspan="1">78</td><td valign="top" align="center" rowspan="1" colspan="1">83</td><td valign="top" align="center" rowspan="1" colspan="1">238 (&#x02212;428, 904)</td><td valign="top" align="center" rowspan="1" colspan="1">744 (&#x02212;8, 1497)</td><td valign="top" align="center" rowspan="1" colspan="1">318 (&#x02212;566, 1203)</td><td valign="top" align="center" rowspan="1" colspan="1">0.473</td></tr></tbody></table><table-wrap-foot><fn id="fn2"><p><sup>a</sup>Mean difference, adjusted for baseline value, stratification categories (age, ethnicity, metformin) and change in accelerometer wear time; <sup>b</sup>significance of the intervention term in the model; <sup>c</sup>those with missing data excluded; <sup>d</sup>those who did not attend the structured education programme have been excluded from the intervention arm; <sup>e</sup>multiple imputation for missing data.</p></fn><fn id="fn3"><p>CI, confidence interval.</p></fn></table-wrap-foot></table-wrap>
</p><p>No clinically significant changes in BMI, lipids, glucose indices and other indices of physical activity were found (<xref ref-type="table" rid="tbl3">Table 3</xref> and also <ext-link ext-link-type="uri" xlink:href="http://www.endocrineconnections.org/cgi/content/full/EC-17-0274/DC1">Supplementary Tables 2</ext-link> and <ext-link ext-link-type="uri" xlink:href="http://www.endocrineconnections.org/cgi/content/full/EC-17-0274/DC1">3</ext-link>).
<table-wrap id="tbl3" position="float"><label>Table 3</label><caption><p>Changes in anthropometric and biomedical outcomes at 12 months follow-up.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="2" colspan="1"/><th valign="top" align="center" colspan="2" rowspan="1"><bold>No. of participants</bold></th><th valign="top" align="center" colspan="2" rowspan="1"><bold>Mean change from baseline</bold> (95% CI)</th><th valign="top" align="center" colspan="2" rowspan="1"><bold>Model summary<sup>a</sup></bold></th></tr><tr><th valign="top" align="center" rowspan="1" colspan="1">Control</th><th valign="top" align="center" rowspan="1" colspan="1">Intervention</th><th valign="top" align="center" rowspan="1" colspan="1">Control</th><th valign="top" align="center" rowspan="1" colspan="1">Intervention</th><th valign="top" align="center" rowspan="1" colspan="1">Coefficient (95% CI)</th><th valign="top" align="center" rowspan="1" colspan="1"><italic>P</italic> value<sup>b</sup></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Weight (kg)</td><td valign="top" align="center" rowspan="1" colspan="1">52</td><td valign="top" align="center" rowspan="1" colspan="1">48</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.43 (&#x02212;2.54, 1.69)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;1.74 (&#x02212;3.61, 0.14)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;1.33 (&#x02212;4.14, 1.48)</td><td valign="top" align="center" rowspan="1" colspan="1">0.351</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td valign="top" align="center" rowspan="1" colspan="1">52</td><td valign="top" align="center" rowspan="1" colspan="1">48</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.12 (&#x02212;0.88, 0.63)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.66 (&#x02212;1.34, 0.02)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.56 (&#x02212;1.57, 0.45)</td><td valign="top" align="center" rowspan="1" colspan="1">0.273</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Systolic blood pressure (mmHg)</td><td valign="top" align="center" rowspan="1" colspan="1">52</td><td valign="top" align="center" rowspan="1" colspan="1">48</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;3.17 (&#x02212;6.24, &#x02212;0.10)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;2.70 (&#x02212;6.00, 0.57)</td><td valign="top" align="center" rowspan="1" colspan="1">0.49 (&#x02212;3.31, 4.30)</td><td valign="top" align="center" rowspan="1" colspan="1">0.797</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Diastolic blood pressure (mmHg)</td><td valign="top" align="center" rowspan="1" colspan="1">52</td><td valign="top" align="center" rowspan="1" colspan="1">48</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;1.13 (&#x02212;3.70, 1.43)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;2.24 (&#x02212;4.78, &#x02212;0.30)</td><td valign="top" align="center" rowspan="1" colspan="1">0.40 (&#x02212;3.14, 3.94)</td><td valign="top" align="center" rowspan="1" colspan="1">0.822</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Fasting glucose (mmol/L)</td><td valign="top" align="center" rowspan="1" colspan="1">52</td><td valign="top" align="center" rowspan="1" colspan="1">48</td><td valign="top" align="center" rowspan="1" colspan="1">0.04 (&#x02212;0.07, 0.16)</td><td valign="top" align="center" rowspan="1" colspan="1">0.03 (&#x02212;0.06, 0.11)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.01 (&#x02212;0.16, 0.13)</td><td valign="top" align="center" rowspan="1" colspan="1">0.865</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">2-h glucose (mmol/L)</td><td valign="top" align="center" rowspan="1" colspan="1">51</td><td valign="top" align="center" rowspan="1" colspan="1">47</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.66 (&#x02212;1.06, &#x02212;0.25)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.26 (&#x02212;0.77, 0.25)</td><td valign="top" align="center" rowspan="1" colspan="1">0.42 (&#x02212;0.12, 0.97)</td><td valign="top" align="center" rowspan="1" colspan="1">0.128</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Haemoglobin A<sub>1c</sub> (mmol/mol)</td><td valign="top" align="center" rowspan="1" colspan="1">52</td><td valign="top" align="center" rowspan="1" colspan="1">48</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;4.06 (&#x02212;4.92, &#x02212;3.20)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;5.66 (&#x02212;7.41, &#x02212;3.90)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;1.08 (&#x02212;2.87, 0.70)</td><td valign="top" align="center" rowspan="1" colspan="1">0.232</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Insulin (IU/L)</td><td valign="top" align="center" rowspan="1" colspan="1">47</td><td valign="top" align="center" rowspan="1" colspan="1">40</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;1.73 (&#x02212;3.23, &#x02212;0.24)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;1.48 (&#x02212;4.10, 1.13)</td><td valign="top" align="center" rowspan="1" colspan="1">0.54 (&#x02212;1.74, 2.81)</td><td valign="top" align="center" rowspan="1" colspan="1">0.640</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">HOMA-IR</td><td valign="top" align="center" rowspan="1" colspan="1">47</td><td valign="top" align="center" rowspan="1" colspan="1">40</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.38 (&#x02212;0.73, &#x02212;0.04)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.29 (&#x02212;0.92, 0.34)</td><td valign="top" align="center" rowspan="1" colspan="1">0.17 (&#x02212;0.39, 0.73)</td><td valign="top" align="center" rowspan="1" colspan="1">0.554</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Total cholesterol (mmol/L)</td><td valign="top" align="center" rowspan="1" colspan="1">51</td><td valign="top" align="center" rowspan="1" colspan="1">48</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.13 (&#x02212;0.33, 0.07)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.23 (&#x02212;0.44, &#x02212;0.02)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.12 (&#x02212;0.38, 0.15)</td><td valign="top" align="center" rowspan="1" colspan="1">0.385</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">HDL cholesterol (mmol/L)</td><td valign="top" align="center" rowspan="1" colspan="1">51</td><td valign="top" align="center" rowspan="1" colspan="1">47</td><td valign="top" align="center" rowspan="1" colspan="1">0.02 (&#x02212;0.06, 0.09)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.02 (&#x02212;0.10, 0.06)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.03 (&#x02212;0.13, 0.07)</td><td valign="top" align="center" rowspan="1" colspan="1">0.558</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">LDL cholesterol (mmol/L)</td><td valign="top" align="center" rowspan="1" colspan="1">51</td><td valign="top" align="center" rowspan="1" colspan="1">46</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.16 (&#x02212;0.34, 0.01)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.17 (&#x02212;0.34, &#x02212;0.002)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.04 (&#x02212;0.26, 0.18)</td><td valign="top" align="center" rowspan="1" colspan="1">0.726</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Triglyceride (mmol/L)</td><td valign="top" align="center" rowspan="1" colspan="1">51</td><td valign="top" align="center" rowspan="1" colspan="1">48</td><td valign="top" align="center" rowspan="1" colspan="1">0.06 (&#x02212;0.13, 0.24)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.20 (&#x02212;0.38, 0.02)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.15 (&#x02212;0.36, 0.06)</td><td valign="top" align="center" rowspan="1" colspan="1">0.169</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">SHBG (mmol/L)</td><td valign="top" align="center" rowspan="1" colspan="1">51</td><td valign="top" align="center" rowspan="1" colspan="1">47</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;1.45 (&#x02212;10.02, 7.12)</td><td valign="top" align="center" rowspan="1" colspan="1">1.70 (&#x02212;8.89, 12.30)</td><td valign="top" align="center" rowspan="1" colspan="1">5.01 (&#x02212;7.08, 17.10)</td><td valign="top" align="center" rowspan="1" colspan="1">0.413</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Testosterone (nmol/L)</td><td valign="top" align="center" rowspan="1" colspan="1">49</td><td valign="top" align="center" rowspan="1" colspan="1">47</td><td valign="top" align="center" rowspan="1" colspan="1">0.10 (&#x02212;0.20, 0.40)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.002 (&#x02212;0.20, 0.20)</td><td valign="top" align="center" rowspan="1" colspan="1">0.01 (&#x02212;0.34, 0.35)</td><td valign="top" align="center" rowspan="1" colspan="1">0.968</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Vitamin D (ng/mL)</td><td valign="top" align="center" rowspan="1" colspan="1">51</td><td valign="top" align="center" rowspan="1" colspan="1">47</td><td valign="top" align="center" rowspan="1" colspan="1">12.90 (6.28, 19.52)</td><td valign="top" align="center" rowspan="1" colspan="1">5.83 (&#x02212;0.28, 11.94)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;7.85 (&#x02212;16.15, 0.45)</td><td valign="top" align="center" rowspan="1" colspan="1">0.063</td></tr></tbody></table><table-wrap-foot><fn id="fn4"><p><sup>a</sup>Difference between treatment groups, adjusted for baseline value, stratification categories (age, ethnicity, metformin); <sup>b</sup>significance of the intervention term in the model.</p></fn><fn id="fn5"><p>CI, confidence interval; SHBG, Sex Hormone-Binding Globulin.</p></fn></table-wrap-foot></table-wrap>
</p><p>The education programme significantly improved participants&#x02019; &#x02018;understanding&#x02019; (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001) and &#x02018;control&#x02019; (<italic>P</italic>&#x02009;=&#x02009;0.002) of their condition (<xref ref-type="table" rid="tbl4">Table 4</xref>). The intervention also improved their QoL in three dimensions of PCOSQ; &#x02018;emotions&#x02019;, &#x02018;fertility&#x02019; and &#x02018;weight&#x02019; (<italic>P</italic>&#x02009;=&#x02009;0.035, <italic>P</italic>&#x02009;=&#x02009;0.035 and <italic>P</italic>&#x02009;=&#x02009;0.009 respectively) as well as the mental component score from the SF-12 questionnaire; mean difference 5.79 (95% CI 1.74, 9.84, <italic>P</italic>&#x02009;=&#x02009;0.006).
<table-wrap id="tbl4" position="float"><label>Table 4</label><caption><p>Scores for belief in illness, health-related quality of life and SF-12 at 12 months follow.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="2" colspan="1"/><th valign="top" align="center" colspan="2" rowspan="1"><bold>Median</bold> (IQR)</th><th valign="top" align="center" colspan="2" rowspan="1"><bold>Model summary</bold><sup>a</sup></th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">Control</th><th valign="top" align="center" rowspan="1" colspan="1">Intervention</th><th valign="top" align="center" rowspan="1" colspan="1">Coefficient (95% CI)</th><th valign="top" align="center" rowspan="1" colspan="1"><italic>P</italic> value<sup>b</sup></th></tr></thead><tbody><tr><td valign="top" align="left" colspan="5" rowspan="1">Brief IP<sup>c</sup></td></tr><tr><td valign="top" align="left" colspan="5" rowspan="1">&#x02003;Consequences (How much does your PCOS affects your life?)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Baseline</td><td valign="top" align="center" rowspan="1" colspan="1">7 (5&#x02013;8)</td><td valign="top" align="center" rowspan="1" colspan="1">7 (5&#x02013;8)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;12 months</td><td valign="top" align="center" rowspan="1" colspan="1">6 (4&#x02013;7)</td><td valign="top" align="center" rowspan="1" colspan="1">6 (3.5&#x02013;6)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.15 (&#x02212;1.10, 0.81)</td><td valign="top" align="center" rowspan="1" colspan="1">0.761</td></tr><tr><td valign="top" align="left" colspan="5" rowspan="1">&#x02003;Timeline (How long do you think your PCOS will continue?)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Baseline</td><td valign="top" align="center" rowspan="1" colspan="1">10 (8&#x02013;10)</td><td valign="top" align="center" rowspan="1" colspan="1">10 (8&#x02013;10)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;12 months</td><td valign="top" align="center" rowspan="1" colspan="1">10 (8&#x02013;10)</td><td valign="top" align="center" rowspan="1" colspan="1">10 (7.5&#x02013;10)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.21 (&#x02212;1.20, 0.77)</td><td valign="top" align="center" rowspan="1" colspan="1">0.663</td></tr><tr><td valign="top" align="left" colspan="5" rowspan="1">&#x02003;Personal control (How much control do you believe you have over your PCOS?)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Baseline</td><td valign="top" align="center" rowspan="1" colspan="1">4 (3&#x02013;5)</td><td valign="top" align="center" rowspan="1" colspan="1">4 (2&#x02013;5)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;12 months</td><td valign="top" align="center" rowspan="1" colspan="1">4 (2&#x02013;6)</td><td valign="top" align="center" rowspan="1" colspan="1">6 (4&#x02013;7)</td><td valign="top" align="center" rowspan="1" colspan="1">1.65 (0.62, 2.69)</td><td valign="top" align="center" rowspan="1" colspan="1">0.002</td></tr><tr><td valign="top" align="left" colspan="5" rowspan="1">&#x02003;Treatment control (How much do you think treatment can help your PCOS?)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Baseline</td><td valign="top" align="center" rowspan="1" colspan="1">7 (5&#x02013;7)</td><td valign="top" align="center" rowspan="1" colspan="1">6 (4&#x02013;8)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;12 months</td><td valign="top" align="center" rowspan="1" colspan="1">5 (5&#x02013;8)</td><td valign="top" align="center" rowspan="1" colspan="1">5 (4&#x02013;7)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.42 (&#x02212;1.58, 0.74)</td><td valign="top" align="center" rowspan="1" colspan="1">0.474</td></tr><tr><td valign="top" align="left" colspan="5" rowspan="1">&#x02003;Identity (How much do you experience symptoms from your PCOS?)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Baseline</td><td valign="top" align="center" rowspan="1" colspan="1">6 (5&#x02013;7)</td><td valign="top" align="center" rowspan="1" colspan="1">7 (6&#x02013;8)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;12 months</td><td valign="top" align="center" rowspan="1" colspan="1">6 (5&#x02013;8)</td><td valign="top" align="center" rowspan="1" colspan="1">7 (5.5&#x02013;7)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.32 (&#x02212;1.24, 0.59)</td><td valign="top" align="center" rowspan="1" colspan="1">0.482</td></tr><tr><td valign="top" align="left" colspan="5" rowspan="1">&#x02003;Concern (How concerned are you about your PCOS?)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Baseline</td><td valign="top" align="center" rowspan="1" colspan="1">7 (6&#x02013;9)</td><td valign="top" align="center" rowspan="1" colspan="1">7 (6&#x02013;9)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;12 months</td><td valign="top" align="center" rowspan="1" colspan="1">6 (4&#x02013;8)</td><td valign="top" align="center" rowspan="1" colspan="1">6 (4.5&#x02013;7)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.21 (&#x02212;1.28, 0.86)</td><td valign="top" align="center" rowspan="1" colspan="1">0.695</td></tr><tr><td valign="top" align="left" colspan="5" rowspan="1">&#x02003;Coherence (How well do you feel you understand your PCOS?)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Baseline</td><td valign="top" align="center" rowspan="1" colspan="1">6 (4&#x02013;7)</td><td valign="top" align="center" rowspan="1" colspan="1">6 (4&#x02013;7)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;12 months</td><td valign="top" align="center" rowspan="1" colspan="1">6 (5&#x02013;8)</td><td valign="top" align="center" rowspan="1" colspan="1">8 (7&#x02013;9)</td><td valign="top" align="center" rowspan="1" colspan="1">1.35 (0.62, 2.07)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td valign="top" align="left" colspan="5" rowspan="1">&#x02003;Emotional representation (How much does your PCOS affect you emotionally? E.g. Does it make you angry, scared, upset, or depressed?)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Baseline</td><td valign="top" align="center" rowspan="1" colspan="1">7 (5&#x02013;9)</td><td valign="top" align="center" rowspan="1" colspan="1">7 (4.5&#x02013;8.5)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;12 months</td><td valign="top" align="center" rowspan="1" colspan="1">7 (5&#x02013;8)</td><td valign="top" align="center" rowspan="1" colspan="1">5 (3.5&#x02013;7)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.67 (&#x02212;1.58, 0.25)</td><td valign="top" align="center" rowspan="1" colspan="1">0.151</td></tr><tr><td valign="top" align="left" colspan="5" rowspan="1">Health-related quality of life<sup>d</sup></td></tr><tr><td valign="top" align="left" colspan="5" rowspan="1">&#x02003;PCOSQ emotions</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Baseline</td><td valign="top" align="center" rowspan="1" colspan="1">4.5 (3.4&#x02013;5.3)</td><td valign="top" align="center" rowspan="1" colspan="1">4.9 (3.8&#x02013;5.7)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;12 months</td><td valign="top" align="center" rowspan="1" colspan="1">4.7 (3.6&#x02013;5.6)</td><td valign="top" align="center" rowspan="1" colspan="1">5.6 (4.3&#x02013;6.1)</td><td valign="top" align="center" rowspan="1" colspan="1">0.47 (0.04, 0.91)</td><td valign="top" align="center" rowspan="1" colspan="1">0.035</td></tr><tr><td valign="top" align="left" colspan="5" rowspan="1">&#x02003;PCOSQ fertility</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Baseline</td><td valign="top" align="center" rowspan="1" colspan="1">4.1 (2.8&#x02013;6.0)</td><td valign="top" align="center" rowspan="1" colspan="1">5.0 (2.9&#x02013;6.5)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;12 months</td><td valign="top" align="center" rowspan="1" colspan="1">4.9 (3.5&#x02013;6.3)</td><td valign="top" align="center" rowspan="1" colspan="1">6.3 (4.6&#x02013;6.8)</td><td valign="top" align="center" rowspan="1" colspan="1">0.52 (0.04, 1.00)</td><td valign="top" align="center" rowspan="1" colspan="1">0.035</td></tr><tr><td valign="top" align="left" colspan="5" rowspan="1">&#x02003;PCOSQ hair</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Baseline</td><td valign="top" align="center" rowspan="1" colspan="1">4.4 (2.1&#x02013;6.2)</td><td valign="top" align="center" rowspan="1" colspan="1">3.2 (2.2&#x02013;5.1)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;12 months</td><td valign="top" align="center" rowspan="1" colspan="1">4.0 (2.7&#x02013;5.8)</td><td valign="top" align="center" rowspan="1" colspan="1">4.0 (2.8&#x02013;5.3)</td><td valign="top" align="center" rowspan="1" colspan="1">0.19 (&#x02212;0.29, 0.67)</td><td valign="top" align="center" rowspan="1" colspan="1">0.441</td></tr><tr><td valign="top" align="left" colspan="5" rowspan="1">&#x02003;PCOSQ menstruation</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Baseline</td><td valign="top" align="center" rowspan="1" colspan="1">3.9 (2.6&#x02013;4.9)</td><td valign="top" align="center" rowspan="1" colspan="1">3.8 (2.8&#x02013;5.0)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;12 months</td><td valign="top" align="center" rowspan="1" colspan="1">4.3 (3.0&#x02013;5.3)</td><td valign="top" align="center" rowspan="1" colspan="1">4.5 (3.4&#x02013;5.6)</td><td valign="top" align="center" rowspan="1" colspan="1">0.20 (&#x02212;0.42, 0.82)</td><td valign="top" align="center" rowspan="1" colspan="1">0.520</td></tr><tr><td valign="top" align="left" colspan="5" rowspan="1">&#x02003;PCOSQ weight</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Baseline</td><td valign="top" align="center" rowspan="1" colspan="1">2.4 (1.2&#x02013;3.5)</td><td valign="top" align="center" rowspan="1" colspan="1">2.4 (1.2&#x02013;3.4)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;12 months</td><td valign="top" align="center" rowspan="1" colspan="1">2.4 (1.6&#x02013;3.9)</td><td valign="top" align="center" rowspan="1" colspan="1">3.8 (2.2&#x02013;4.4)</td><td valign="top" align="center" rowspan="1" colspan="1">0.62 (0.16, 1.09)</td><td valign="top" align="center" rowspan="1" colspan="1">0.009</td></tr><tr><td valign="top" align="left" colspan="5" rowspan="1">&#x02003;SF-12<sup>e</sup> physical component score</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Baseline</td><td valign="top" align="center" rowspan="1" colspan="1">53.0 (45.6&#x02013;56.3)</td><td valign="top" align="center" rowspan="1" colspan="1">54.1 (51.1&#x02013;57.3)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;12 months</td><td valign="top" align="center" rowspan="1" colspan="1">54.5 (48.2&#x02013;59.0)</td><td valign="top" align="center" rowspan="1" colspan="1">54.5 (49.9&#x02013;58.3)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.57 (&#x02212;3.49, 2.36)</td><td valign="top" align="center" rowspan="1" colspan="1">0.701</td></tr><tr><td valign="top" align="left" colspan="5" rowspan="1">&#x02003;SF-12<sup>e</sup> mental component score</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Baseline</td><td valign="top" align="center" rowspan="1" colspan="1">47.3 (39.5&#x02013;52.5)</td><td valign="top" align="center" rowspan="1" colspan="1">47.3 (40.2&#x02013;52.8)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;12 months</td><td valign="top" align="center" rowspan="1" colspan="1">39.9 (32.6&#x02013;51.7)</td><td valign="top" align="center" rowspan="1" colspan="1">49.4 (42.3&#x02013;55.5)</td><td valign="top" align="center" rowspan="1" colspan="1">5.79 (1.74, 9.84)</td><td valign="top" align="center" rowspan="1" colspan="1">0.006</td></tr></tbody></table><table-wrap-foot><fn id="fn6"><p><sup>a</sup>Difference between treatment groups, adjusted for baseline value, stratification categories (age, ethnicity, metformin); <sup>b</sup>significance of the intervention term in the model; <sup>c</sup>brief illness perception questionnaire: scoring out of 10 (<italic>N</italic>&#x02009;=&#x02009;68, control 31, intervention 37); <sup>d</sup>PCOS questionnaire: scoring out of 7 (<italic>N</italic>&#x02009;=&#x02009;89, control 44, intervention 45); higher scores suggests that PCOS does not have an impact on the quality of life; <sup>e</sup>SF-12 questionnaire: scoring out of 100 (<italic>N</italic>&#x02009;=&#x02009;89, control 45, intervention 44); higher scores indicate a better level of health.</p></fn><fn id="fn7"><p>CI, confidence interval; IQR, interquartile range; PCOSQ, PCOS questionnaire.</p></fn></table-wrap-foot></table-wrap>
</p><p>Participants&#x02019; had feelings of &#x02018;loneliness&#x02019;, &#x02018;annoyance&#x02019;, &#x02018;ashamed&#x02019;, &#x02018;confused&#x02019;, &#x02018;depressed&#x02019; or &#x02018;fear&#x02019; about their PCOS as well as sense of &#x02018;relief&#x02019; after having a diagnosis. <ext-link ext-link-type="uri" xlink:href="http://www.endocrineconnections.org/cgi/content/full/EC-17-0274/DC1">Supplementary Figure 2</ext-link> shows an example of their reflection and <xref ref-type="fig" rid="fig2">Fig. 2</xref> the word cloud summary (<ext-link ext-link-type="uri" xlink:href="http://www.wordle.net/">http://www.wordle.net/</ext-link>).
<fig fig-type="figure" id="fig2" position="float"><label>Figure 2</label><caption><p>Word cloud summary of feelings of women with PCOS towards their condition and when they found out they had PCOS http://www.wordle.net/. (Larger words have been repeated more frequently.)</p></caption><graphic xlink:href="ec-7-26-g002"/></fig>
</p><p>On reflection on the education programme, participants&#x02019; &#x02018;best bits&#x02019; were &#x02018;meeting others with PCOS&#x02019; and &#x02018;gaining knowledge about the condition and lifestyle&#x02019; and &#x02018;key messages&#x02019; were &#x02018;being positive about PCOS&#x02019;, &#x02018;benefits of the diet and exercise&#x02019; and the &#x02018;concept of insulin resistance&#x02019;.</p></sec><sec><title>Discussion</title><p>A single exposure to a structured education programme did not increase physical activity or improve biochemical markers in overweight and obese women with PCOS. It did, however, improve mental health and well-being in secondary outcome analyses.</p><p>To our knowledge, no other structured education programme exists, which addresses multidimensional needs of women with PCOS and therefore direct comparison with literature was not possible. However, elements of the programme can be compared.</p><p>In a single arm study (<xref rid="bib24" ref-type="bibr">24</xref>), women with PCOS were encouraged to increase their walking activity, which improved fitness but not BMI or cholesterol. Successful studies in women with PCOS have had multiple sessions of supervised exercise (<xref rid="bib18" ref-type="bibr">18</xref>), which is not pragmatic in routine clinical practice. Structured education programmes in non-PCOS cohorts have had mixed outcomes: improved physical activity in an older cohort (average age &#x0003e;60 years) (<xref rid="bib10" ref-type="bibr">10</xref>) or no change in a younger, mixed gender group (average age &#x0003c;35 years) (<xref rid="bib25" ref-type="bibr">25</xref>). Multiple, weekly sessions in women (not necessarily those with PCOS) have increased walking activity by 2000 steps (<xref rid="bib26" ref-type="bibr">26</xref>). In our study, we aimed for a larger cohort and offered one exposure to the education programme, following the then recommendations for diabetes (<xref rid="bib27" ref-type="bibr">27</xref>). Current recommendations are different and suggest a minimum of 16&#x02009;h/year contact time (<xref rid="bib28" ref-type="bibr">28</xref>). In our cohort, the 6-month results are slightly more favourable than 12 months. This is perhaps an indication of the short-term impact of such educational interventions and the need for reminder sessions or breaking the 7-h education to shorter session to be delivered over a longer period of time.</p><p>Structured education in other chronic conditions has shown to improve IP and/or QoL (<xref rid="bib29" ref-type="bibr">29</xref>, <xref rid="bib30" ref-type="bibr">30</xref>, <xref rid="bib31" ref-type="bibr">31</xref>). Reported feelings of living with PCOS, namely anger, confusion and frustration (<xref ref-type="fig" rid="fig2">Fig. 2</xref>), were examples of the psychological challenge that some of the participants experienced. Sense of relief after being diagnosed with PCOS was perhaps a reflection of the psychological impact of the symptoms and an indication of the reported lack of information for these women (<xref rid="bib5" ref-type="bibr">5</xref>, <xref rid="bib8" ref-type="bibr">8</xref>, <xref rid="bib9" ref-type="bibr">9</xref>). It is suggested that such psychological factors are potential barriers for successful lifestyle interventions and require further addressing (<xref rid="bib9" ref-type="bibr">9</xref>). It is therefore possible to assume that provision of an education programme like our study, at an earlier opportunity as close to the time of diagnosis, can improve well-being by improving IP (coherence and control) and reducing their anxiety around emotions, fertility and weight.</p><p>Participants in the SUCCESS education programme indicated meeting other people with PCOS as one of the &#x02018;best bits&#x02019; of the education. Attending group education has had the potential benefit of meeting others with a similar condition, which in fact reduced their anxiety of &#x02018;why me&#x02019;, &#x02018;unfair&#x02019; and feeling &#x02018;lonely&#x02019;. Providing structured group education for chronic conditions with a potential element of peer support can improve the outcome of other treatment interventions.</p><sec><title>Strength and limitations</title><p>The major limitation of the study was the high attrition rate (38%) at the end of study (32% at 6 month follow-up). It is worth noting that only 23% of the intervention arm did not attend the education. This could be an indication of their information need; they spared time for the education, while competing life activities (85% employed or student) perhaps prevented attendance at the clinical visits.</p><p>Second major limitation for the primary outcome was the use of the accelerometer. Although a useful tool to capture physical activities, it contributed to substantial missing data in our study due to loss in the post, strict validity criteria and inability to capture some activities (e.g. cycling and swimming).</p><p>Considering that this was the first attempt at developing a tailored education programme for women with PCOS and the high prevalence of overweight and obesity in PCOS (<xref rid="bib2" ref-type="bibr">2</xref>, <xref rid="bib21" ref-type="bibr">21</xref>), the inclusion criteria were limited to overweight and obese women to ensure a more metabolically homogenous cohort. The study design, however, avoided any interference with participants&#x02019; routine medical care and therefore the education programme can potentially be implemented in the speciality clinics or primary care services similarly.</p></sec></sec><sec><title>Conclusion and implications</title><p>The outcomes of our study are important in the provision of care for women affected by PCOS; providing information in a structured approach to ensure improved IP should be part of the treatment offered to women with PCOS especially in the context of patient-centred care. Although a single exposure to structured education did not improve physical activity, BMI or biochemical markers. It did, however, improve their understanding of their disease and their QoL. Interim reminder sessions might have improved these outcomes and should be further explored in future research.</p><p>In implementation of our findings, we aim to make education sessions available for all of our patients with PCOS in a more regular basis; sign post them to the currently available support groups and in future funding applications consider the design of web-based education interventions in conjunction with the group-based interventions.</p></sec><sec sec-type="supplementary-material" id="supp1"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SD1"><caption><title>Supporting Figure 1</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="ec-7-26-s001.pdf" xlink:type="simple" id="d35e1893" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD2"><caption><title>Supporting Figure 2</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="ec-7-26-s002.pdf" xlink:type="simple" id="d35e1898" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD3"><caption><title>Supporting Figure 3</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="ec-7-26-s003.pdf" xlink:type="simple" id="d35e1903" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD4"><caption><title>Supplementary Material 1</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="ec-7-26-s004.pdf" xlink:type="simple" id="d35e1908" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD5"><caption><title>Supplementary Material 2</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="ec-7-26-s005.pdf" xlink:type="simple" id="d35e1913" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD6"><caption><title>Supporting Table 1</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="ec-7-26-t001.pdf" xlink:type="simple" id="d35e1918" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD7"><caption><title>Supporting Table 2</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="ec-7-26-t002.pdf" xlink:type="simple" id="d35e1923" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD8"><caption><title>Supporting Table 3</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="ec-7-26-t003.pdf" xlink:type="simple" id="d35e1928" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD9"><caption><title>Supporting Table 4</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="ec-7-26-t004.pdf" xlink:type="simple" id="d35e1933" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD10"><caption><title>Supporting Table 5</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="ec-7-26-t005.pdf" xlink:type="simple" id="d35e1938" position="anchor"/></supplementary-material></sec><sec><title>Declaration of interest</title><p>The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.</p></sec><sec><title>Funding</title><p>Supported by Diabetes Research Centre, University of Leicester, through funds from National Institute for Health Research (NIHR) and NIHR Collaboration for Leadership in Applied Health Research and Care &#x02013; East Midlands and the NIHR Leicester &#x02013; Biomedical Research Centre, a partnership between University Hospitals of Leicester NHS Trust, Loughborough University and the University of Leicester. &#x02018;Early Career Grant&#x02019; from Society for Endocrinology (HM). (The views expressed are those of the authors and not necessarily the above mentioned organisations).</p></sec><sec><title>Author contribution statement</title><p>Conception of the research question was by H M, H D, M J D and K K; analysis by Y C, D B and L G. C E processed the accelerometer data. H M, J B, H D and M H developed the education programme. Paper was drafted by H M and reviewed and commented by all authors.</p></sec></body><back><ack><title>Acknowledgments</title><p>Authors acknowledge the help from patients and wider team at Leicester Diabetes Centre; nurses, administrators, management, education and creative art design group.</p></ack><ref-list><title>References</title><ref id="bib1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barry</surname><given-names>JA</given-names></name><name><surname>Kuczmierczyk</surname><given-names>AR</given-names></name><name><surname>Hardiman</surname><given-names>PJ.</given-names></name></person-group>
<article-title>Anxiety and depression in polycystic ovary syndrome: a systematic review and meta-analysis</article-title>. <source>Human Reproduction</source>
<year>2011</year>
<volume>26</volume>
<fpage>2442</fpage>&#x02013;<lpage>2451</lpage>. (<pub-id pub-id-type="doi">10.1093/humrep/der197</pub-id>)<pub-id pub-id-type="pmid">21725075</pub-id></mixed-citation></ref><ref id="bib2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fauser</surname><given-names>BC</given-names></name><name><surname>Tarlatzis</surname><given-names>BC</given-names></name><name><surname>Rebar</surname><given-names>RW</given-names></name><name><surname>Legro</surname><given-names>RS</given-names></name><name><surname>Balen</surname><given-names>AH</given-names></name><name><surname>Lobo</surname><given-names>R</given-names></name><name><surname>Carmina</surname><given-names>E</given-names></name><name><surname>Chang</surname><given-names>J</given-names></name><name><surname>Yildiz</surname><given-names>BO</given-names></name><name><surname>Laven</surname><given-names>JS</given-names></name><etal/></person-group>
<article-title>Consensus on women&#x02019;s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group</article-title>. <source>Fertility and Sterility</source>
<year>2012</year>
<volume>97</volume>
<fpage>28.e25</fpage>&#x02013;<lpage>38.e25</lpage>. (<pub-id pub-id-type="doi">10.1016/j.fertnstert.2011.09.024</pub-id>)<pub-id pub-id-type="pmid">22153789</pub-id></mixed-citation></ref><ref id="bib3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mani</surname><given-names>H</given-names></name><name><surname>Levy</surname><given-names>MJ</given-names></name><name><surname>Davies</surname><given-names>MJ</given-names></name><name><surname>Morris</surname><given-names>DH</given-names></name><name><surname>Gray</surname><given-names>LJ</given-names></name><name><surname>Bankart</surname><given-names>J</given-names></name><name><surname>Blackledge</surname><given-names>H</given-names></name><name><surname>Khunti</surname><given-names>K</given-names></name><name><surname>Howlett</surname><given-names>TA</given-names></name></person-group>
<article-title>Diabetes and cardiovascular events in women with polycystic ovary syndrome: a 20-year retrospective cohort study</article-title>. <source>Clinical Endocrinology</source>
<year>2013</year>
<volume>78</volume>
<fpage>926</fpage>&#x02013;<lpage>934</lpage>. (<pub-id pub-id-type="doi">10.1111/cen.12068</pub-id>)<pub-id pub-id-type="pmid">23046078</pub-id></mixed-citation></ref><ref id="bib4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hadjiconstantinou</surname><given-names>M</given-names></name><name><surname>Mani</surname><given-names>H</given-names></name><name><surname>Patel</surname><given-names>N</given-names></name><name><surname>Levy</surname><given-names>M</given-names></name><name><surname>Davies</surname><given-names>MJ</given-names></name><name><surname>Khunti</surname><given-names>K</given-names></name><name><surname>Stone</surname><given-names>M</given-names></name></person-group>
<article-title>Views of women with polycystic ovary syndrome: a qualitative study in an ethnically diverse sample</article-title>. <source>Endocrine Connections</source>
<year>2017</year>
<volume>6</volume>
<fpage>323</fpage>&#x02013;<lpage>330</lpage>. (<pub-id pub-id-type="doi">10.1530/EC-17-0053</pub-id>)<pub-id pub-id-type="pmid">28515051</pub-id></mixed-citation></ref><ref id="bib5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gibson-Helm</surname><given-names>M</given-names></name><name><surname>Teede</surname><given-names>H</given-names></name><name><surname>Dunaif</surname><given-names>A</given-names></name><name><surname>Dokras</surname><given-names>A.</given-names></name></person-group>
<article-title>Delayed diagnosis and a lack of information associated with dissatisfaction in women with polycystic ovary syndrome</article-title>. <source>Journal of Clinical Endocrinology and Metabolism</source>
<year>2016</year>
<volume>102</volume>
<fpage>604</fpage>&#x02013;<lpage>612</lpage>. (<pub-id pub-id-type="doi">10.1210/jc.2016-2963</pub-id>)</mixed-citation></ref><ref id="bib6"><label>6</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>De Silva</surname><given-names>D.</given-names></name></person-group>
<article-title>Evidence: Helping people help themselves</article-title>
<publisher-loc>London, UK</publisher-loc>: <publisher-name>Health Foundation</publisher-name>, <year>2011</year> (available at: <ext-link ext-link-type="uri" xlink:href="http://www.health.org.uk/sites/health/files/HelpingPeopleHelpThemselves.pdf">http://www.health.org.uk/sites/health/files/HelpingPeopleHelpThemselves.pdf</ext-link>)</mixed-citation></ref><ref id="bib7"><label>7</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>NICE</surname><given-names/></name></person-group>
<article-title>The most appropriate means of generic and specific interventions to support attitude and behaviour change at population and community levels. NICE Public health guideline 6 [PH6].</article-title>
<publisher-loc>London, UK</publisher-loc>: <publisher-name>NICE</publisher-name>, <year>2007.</year> (available at: <ext-link ext-link-type="uri" xlink:href="https://www.nice.org.uk/ph6">https://www.nice.org.uk/ph6</ext-link>)</mixed-citation></ref><ref id="bib8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mani</surname><given-names>H</given-names></name><name><surname>Khunti</surname><given-names>K</given-names></name><name><surname>Daly</surname><given-names>H</given-names></name><name><surname>Barnett</surname><given-names>J</given-names></name><name><surname>Davies</surname><given-names>M</given-names></name></person-group>
<article-title>Education and self-management for women with polycystic ovary syndrome; a narrative review of literature</article-title>. <source>Ibnosina Journal of Medicine and Biomedical Sciences</source>
<year>2015</year>
<volume>7</volume>
<fpage>1</fpage>&#x02013;<lpage>9</lpage>. (<pub-id pub-id-type="doi">10.4103/1947-489X.210263</pub-id>)</mixed-citation></ref><ref id="bib9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brennan</surname><given-names>L</given-names></name><name><surname>Teede</surname><given-names>H</given-names></name><name><surname>Skouteris</surname><given-names>H</given-names></name><name><surname>Linardon</surname><given-names>J</given-names></name><name><surname>Hill</surname><given-names>B</given-names></name><name><surname>Moran</surname><given-names>L</given-names></name></person-group>
<article-title>Lifestyle and behavioral management of polycystic ovary syndrome</article-title>. <source>Journal of Women&#x02019;s Health</source>
<year>2017</year>
<volume>26</volume>
<fpage>836</fpage>&#x02013;<lpage>848</lpage>. (<pub-id pub-id-type="doi">10.1089/jwh.2016.5792</pub-id>)</mixed-citation></ref><ref id="bib10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yates</surname><given-names>T</given-names></name><name><surname>Davies</surname><given-names>M</given-names></name><name><surname>Gorely</surname><given-names>T</given-names></name><name><surname>Bull</surname><given-names>F</given-names></name><name><surname>Khunti</surname><given-names>K.</given-names></name></person-group>
<article-title>Effectiveness of a pragmatic education program designed to promote walking activity in individuals with impaired glucose tolerance: a randomized controlled trial</article-title>. <source>Diabetes Care</source>
<year>2009</year>
<volume>32</volume>
<fpage>1404</fpage>&#x02013;<lpage>1410</lpage>. (<pub-id pub-id-type="doi">10.2337/dbib9-0130</pub-id>)<pub-id pub-id-type="pmid">19602539</pub-id></mixed-citation></ref><ref id="bib11"><label>11</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>NICE</surname><given-names/></name></person-group>
<article-title>Assessing body mass index and waist circumference thresholds for intervening to prevent ill health and premature death among adults from black, Asian and other minority ethnic groups in the UK. NICE Public health guideline [PH46].</article-title>
<publisher-loc>London, UK</publisher-loc>: <publisher-name>NICE</publisher-name>, <year>2013.</year> (available at: <ext-link ext-link-type="uri" xlink:href="https://www.nice.org.uk/guidance/ph46">https://www.nice.org.uk/guidance/ph46</ext-link>)</mixed-citation></ref><ref id="bib12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Broadbent</surname><given-names>E</given-names></name><name><surname>Petrie</surname><given-names>KJ</given-names></name><name><surname>Main</surname><given-names>J</given-names></name><name><surname>Weinman</surname><given-names>J.</given-names></name></person-group>
<article-title>The brief illness perception questionnaire</article-title>. <source>Journal of Psychosomatic Research</source>
<year>2006</year>
<volume>60</volume>
<fpage>631</fpage>&#x02013;<lpage>637</lpage>. (<pub-id pub-id-type="doi">10.1016/j.jpsychores.2005.10.020</pub-id>)<pub-id pub-id-type="pmid">16731240</pub-id></mixed-citation></ref><ref id="bib13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cronin</surname><given-names>L</given-names></name><name><surname>Guyatt</surname><given-names>G</given-names></name><name><surname>Griffith</surname><given-names>L</given-names></name><name><surname>Wong</surname><given-names>E</given-names></name><name><surname>Azziz</surname><given-names>R</given-names></name><name><surname>Futterweit</surname><given-names>W</given-names></name><name><surname>Cook</surname><given-names>D</given-names></name><name><surname>Dunaif</surname><given-names>A</given-names></name></person-group>
<article-title>Development of a health-related quality-of-life questionnaire (PCOSQ) for women with polycystic ovary syndrome (PCOS)</article-title>. <source>Journal of Clinical Endocrinology and Metabolism</source>
<year>1998</year>
<volume>83</volume>
<fpage>1976</fpage>&#x02013;<lpage>1987</lpage>. (<pub-id pub-id-type="doi">10.1210/jcem.83.6.4990</pub-id>)<pub-id pub-id-type="pmid">9626128</pub-id></mixed-citation></ref><ref id="bib14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ware</surname><given-names>J</given-names><suffix>Jr</suffix></name><name><surname>Kosinski</surname><given-names>M</given-names></name><name><surname>Keller</surname><given-names>SD.</given-names></name></person-group>
<article-title>A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity</article-title>. <source>Medical Care</source>
<year>1996</year>
<volume>34</volume>
<fpage>220</fpage>&#x02013;<lpage>233</lpage>. (<pub-id pub-id-type="doi">10.1097/00005650-199603000-00003</pub-id>)<pub-id pub-id-type="pmid">8628042</pub-id></mixed-citation></ref><ref id="bib15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mani</surname><given-names>H</given-names></name><name><surname>Potdar</surname><given-names>N</given-names></name><name><surname>Gleeson</surname><given-names>H.</given-names></name></person-group>
<article-title>How to manage an adolescent girl presenting with features of polycystic ovary syndrome (PCOS); an exemplar for adolescent health care in endocrinology</article-title>. <source>Clinical Endocrinology</source>
<year>2014</year>
<volume>81</volume>
<fpage>652</fpage>&#x02013;<lpage>656</lpage>. (<pub-id pub-id-type="doi">10.1111/cen.12501</pub-id>)<pub-id pub-id-type="pmid">24826983</pub-id></mixed-citation></ref><ref id="bib16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mani</surname><given-names>H</given-names></name><name><surname>Khunti</surname><given-names>K</given-names></name><name><surname>Levy</surname><given-names>M</given-names></name><name><surname>Davies</surname><given-names>M.</given-names></name></person-group>
<article-title>Diabetes advice for women with polycystic ovary syndrome; prevention, prevention, prevention</article-title>. <source>Diabetes Management</source>
<year>2013</year>
<volume>3</volume>
<fpage>1</fpage>&#x02013;<lpage>14</lpage>. (<pub-id pub-id-type="doi">10.2217/dmt.13.54</pub-id>)</mixed-citation></ref><ref id="bib17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moran</surname><given-names>LJ</given-names></name><name><surname>Ko</surname><given-names>H</given-names></name><name><surname>Misso</surname><given-names>M</given-names></name><name><surname>Marsh</surname><given-names>K</given-names></name><name><surname>Noakes</surname><given-names>M</given-names></name><name><surname>Talbot</surname><given-names>M</given-names></name><name><surname>Frearson</surname><given-names>M</given-names></name><name><surname>Thondan</surname><given-names>M</given-names></name><name><surname>Stepto</surname><given-names>N</given-names></name><name><surname>Teede</surname><given-names>HJ</given-names></name></person-group>
<article-title>Dietary composition in the treatment of polycystic ovary syndrome: a systematic review to inform evidence-based guidelines</article-title>. <source>Journal of the Academy of Nutrition and Dietetics</source>
<year>2013</year>
<volume>113</volume>
<fpage>520</fpage>&#x02013;<lpage>545</lpage>. (<pub-id pub-id-type="doi">10.1016/j.jand.2012.11.018</pub-id>)<pub-id pub-id-type="pmid">23420000</pub-id></mixed-citation></ref><ref id="bib18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moran</surname><given-names>LJ</given-names></name><name><surname>Hutchison</surname><given-names>SK</given-names></name><name><surname>Norman</surname><given-names>RJ</given-names></name><name><surname>Teede</surname><given-names>HJ.</given-names></name></person-group>
<article-title>Lifestyle changes in women with polycystic ovary syndrome</article-title>. <source>Cochrane Database of Systematic Reviews</source>
<year>2011</year>
<fpage>CD007506</fpage> (<pub-id pub-id-type="doi">10.1002/14651858.CD007506.pub3</pub-id>)</mixed-citation></ref><ref id="bib19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moran</surname><given-names>LJ</given-names></name><name><surname>Pasquali</surname><given-names>R</given-names></name><name><surname>Teede</surname><given-names>HJ</given-names></name><name><surname>Hoeger</surname><given-names>KM</given-names></name><name><surname>Norman</surname><given-names>RJ.</given-names></name></person-group>
<article-title>Treatment of obesity in polycystic ovary syndrome: a position statement of the Androgen Excess and Polycystic Ovary Syndrome Society</article-title>. <source>Fertility and Sterility</source>
<year>2009</year>
<volume>92</volume>
<fpage>1966</fpage>&#x02013;<lpage>1982</lpage>. (<pub-id pub-id-type="doi">10.1016/j.fertnstert.2008.09.018</pub-id>)<pub-id pub-id-type="pmid">19062007</pub-id></mixed-citation></ref><ref id="bib20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harrison</surname><given-names>CL</given-names></name><name><surname>Lombard</surname><given-names>CB</given-names></name><name><surname>Moran</surname><given-names>LJ</given-names></name><name><surname>Teede</surname><given-names>HJ.</given-names></name></person-group>
<article-title>Exercise therapy in polycystic ovary syndrome: a systematic review</article-title>. <source>Human Reproduction Update</source>
<year>2011</year>
<volume>17</volume>
<fpage>171</fpage>&#x02013;<lpage>183</lpage>. (<pub-id pub-id-type="doi">10.1093/humupd/dmq045</pub-id>)<pub-id pub-id-type="pmid">20833639</pub-id></mixed-citation></ref><ref id="bib21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mani</surname><given-names>H</given-names></name><name><surname>Davies</surname><given-names>MJ</given-names></name><name><surname>Bodicoat</surname><given-names>DH</given-names></name><name><surname>Levy</surname><given-names>MJ</given-names></name><name><surname>Gray</surname><given-names>LJ</given-names></name><name><surname>Howlett</surname><given-names>TA</given-names></name></person-group> &#x00026; Khunti K. <article-title>Clinical characteristics of polycystic ovary syndrome: investigating differences in White and South Asian women</article-title>. <source>Clinical Endocrinology</source>
<year>2015</year>
<volume>83</volume>
<fpage>542</fpage>&#x02013;<lpage>549</lpage>. (<pub-id pub-id-type="doi">10.1111/cen.12784</pub-id>)<pub-id pub-id-type="pmid">25824095</pub-id></mixed-citation></ref><ref id="bib22"><label>22</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Mani</surname><given-names>H</given-names></name></person-group>
<article-title>Development of a structured education programme to improve cardiovascular risk in women with polycystic ovary syndrome.</article-title>
<source>PhD Thesis</source>, <publisher-name>University of Leicester</publisher-name>, <year>2014</year> (available at: <ext-link ext-link-type="uri" xlink:href="https://lra.le.ac.uk/handle/2381/28638">https://lra.le.ac.uk/handle/2381/28638</ext-link>)</mixed-citation></ref><ref id="bib23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mani</surname><given-names>H</given-names></name><name><surname>Daly</surname><given-names>H</given-names></name><name><surname>Barnett</surname><given-names>J</given-names></name><name><surname>Levy</surname><given-names>M</given-names></name><name><surname>Khunti</surname><given-names>K</given-names></name><name><surname>Howlett</surname><given-names>T</given-names></name><name><surname>Davies</surname><given-names>M</given-names></name></person-group>
<article-title>The development of a structured education programme to improve cardiovascular risk in women with polycystic ovary syndrome (SUCCESS Study)</article-title>. <source>Endocrine Abstracts</source>
<year>2013</year>
<volume>31</volume>
<fpage>P228</fpage> (<pub-id pub-id-type="doi">10.1530/endoabs.31.P228</pub-id>)</mixed-citation></ref><ref id="bib24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Randeva</surname><given-names>HS</given-names></name><name><surname>Lewandowski</surname><given-names>KC</given-names></name><name><surname>Drzewoski</surname><given-names>J</given-names></name><name><surname>Brooke-Wavell</surname><given-names>K</given-names></name><name><surname>O&#x02019;Callaghan</surname><given-names>C</given-names></name><name><surname>Czupryniak</surname><given-names>L</given-names></name><name><surname>Hillhouse</surname><given-names>EW</given-names></name><name><surname>Prelevic</surname><given-names>GM</given-names></name></person-group>
<article-title>Exercise decreases plasma total homocysteine in overweight young women with polycystic ovary syndrome</article-title>. <source>Journal of Clinical Endocrinology and Metabolism</source>
<year>2002</year>
<volume>87</volume>
<fpage>4496</fpage>&#x02013;<lpage>4501</lpage>. (<pub-id pub-id-type="doi">10.1210/jc.2001-012056</pub-id>)<pub-id pub-id-type="pmid">12364425</pub-id></mixed-citation></ref><ref id="bib25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biddle</surname><given-names>SJ</given-names></name><name><surname>Edwardson</surname><given-names>CL</given-names></name><name><surname>Wilmot</surname><given-names>EG</given-names></name><name><surname>Yates</surname><given-names>T</given-names></name><name><surname>Gorely</surname><given-names>T</given-names></name><name><surname>Bodicoat</surname><given-names>DH</given-names></name><name><surname>Ashra</surname><given-names>N</given-names></name><name><surname>Khunti</surname><given-names>K</given-names></name><name><surname>Nimmo</surname><given-names>MA</given-names></name><name><surname>Davies</surname><given-names>MJ</given-names></name></person-group>
<article-title>A randomised controlled trial to reduce sedentary time in young adults at risk of type 2 diabetes mellitus: project STAND (Sedentary Time ANd Diabetes)</article-title>. <source>PLoS ONE</source>
<year>2015</year>
<volume>10</volume>
<fpage>e0143398</fpage> (<pub-id pub-id-type="doi">10.1371/journal.pone.0143398</pub-id>)<pub-id pub-id-type="pmid">26623654</pub-id></mixed-citation></ref><ref id="bib26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clarke</surname><given-names>KK</given-names></name><name><surname>Freeland-Graves</surname><given-names>J</given-names></name><name><surname>Klohe-Lehman</surname><given-names>DM</given-names></name><name><surname>Milani</surname><given-names>TJ</given-names></name><name><surname>Nuss</surname><given-names>HJ</given-names></name><name><surname>Laffrey</surname><given-names>S.</given-names></name></person-group>
<article-title>Promotion of physical activity in low-income mothers using pedometers</article-title>. <source>Journal of the American Dietetic Association</source>
<year>2007</year>
<volume>107</volume>
<fpage>962</fpage>&#x02013;<lpage>967</lpage>. (<pub-id pub-id-type="doi">10.1016/j.jada.2007.03.010</pub-id>)<pub-id pub-id-type="pmid">17524717</pub-id></mixed-citation></ref><ref id="bib27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haas</surname><given-names>L</given-names></name><name><surname>Maryniuk</surname><given-names>M</given-names></name><name><surname>Beck</surname><given-names>J</given-names></name><name><surname>Cox</surname><given-names>CE</given-names></name><name><surname>Duker</surname><given-names>P</given-names></name><name><surname>Edwards</surname><given-names>L</given-names></name><name><surname>Fisher</surname><given-names>EB</given-names></name><name><surname>Hanson</surname><given-names>L</given-names></name><name><surname>Kent</surname><given-names>D</given-names></name><name><surname>Kolb</surname><given-names>L</given-names></name><etal/></person-group>
<article-title>National standards for diabetes self-management education and support</article-title>. <source>Diabetes Care</source>
<year>2012</year>
<volume>35</volume>
<fpage>2393</fpage>&#x02013;<lpage>2401</lpage>. (<pub-id pub-id-type="doi">10.2337/dc12-1707</pub-id>)<pub-id pub-id-type="pmid">22995096</pub-id></mixed-citation></ref><ref id="bib28"><label>28</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>NICE</surname><given-names/></name></person-group>
<article-title>Preventing type 2 diabetes: risk identification and interventions for individuals at high risk. NICE Public health guidance [PH38].</article-title>
<publisher-loc>London, UK</publisher-loc>: <publisher-name>NICE</publisher-name>, <year>2012</year> (available at: <ext-link ext-link-type="uri" xlink:href="https://www.nice.org.uk/guidance/ph38">https://www.nice.org.uk/guidance/ph38</ext-link>)</mixed-citation></ref><ref id="bib29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname><given-names>MJ</given-names></name><name><surname>Heller</surname><given-names>S</given-names></name><name><surname>Skinner</surname><given-names>TC</given-names></name><name><surname>Campbell</surname><given-names>MJ</given-names></name><name><surname>Carey</surname><given-names>ME</given-names></name><name><surname>Cradock</surname><given-names>S</given-names></name><name><surname>Dallosso</surname><given-names>HM</given-names></name><name><surname>Daly</surname><given-names>H</given-names></name><name><surname>Doherty</surname><given-names>Y</given-names></name><name><surname>Eaton</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Effectiveness of the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cluster randomised controlled trial</article-title>. <source>BMJ</source>
<year>2008</year>
<volume>336</volume>
<fpage>491</fpage>&#x02013;<lpage>495</lpage>. (<pub-id pub-id-type="doi">10.1136/bmj.39474.922025.BE</pub-id>)<pub-id pub-id-type="pmid">18276664</pub-id></mixed-citation></ref><ref id="bib30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zwerink M</surname></name><name><surname>Brusse-Keizer</surname><given-names>M</given-names></name><name><surname>van der Valk</surname><given-names>PD</given-names></name><name><surname>Zielhuis</surname><given-names>GA</given-names></name><name><surname>Monninkhof</surname><given-names>EM</given-names></name><name><surname>van der Palen</surname><given-names>J</given-names></name><name><surname>Frith</surname><given-names>PA</given-names></name><name><surname>Effing</surname><given-names>T</given-names></name></person-group>
<article-title>Self management for patients with chronic obstructive pulmonary disease</article-title>. <source>Cochrane Database of Systematic Reviews</source>
<year>2014</year>
<fpage>CD002990</fpage> (<pub-id pub-id-type="doi">10.1002/14651858.CD002990.pub3</pub-id>)<pub-id pub-id-type="pmid">24665053</pub-id></mixed-citation></ref><ref id="bib31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kroon</surname><given-names>FP</given-names></name><name><surname>van der Burg</surname><given-names>LR</given-names></name><name><surname>Buchbinder</surname><given-names>R</given-names></name><name><surname>Osborne</surname><given-names>RH</given-names></name><name><surname>Johnston</surname><given-names>RV</given-names></name><name><surname>Pitt</surname><given-names>V.</given-names></name></person-group>
<article-title>Self-management education programmes for osteoarthritis</article-title>. <source>Cochrane Database of Systematic Reviews</source>
<year>2014</year>
<fpage>CD008963</fpage> (<pub-id pub-id-type="doi">10.1002/14651858.CD008963.pub2</pub-id>)<pub-id pub-id-type="pmid">24425500</pub-id></mixed-citation></ref></ref-list></back></article>